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The aim of this study was to analyze whether tyrosine phosphorylation in tumoral arteries may modulate their vascular response.
To do this, mesenteric arteries supplying blood flow to colorectal tumors or to normal intestine were obtained during surgery and
prepared for isometric tension recording in an organ bath. Increasing tyrosine phosphorylation with the phosphatase inhibitor,
sodium orthovanadate produced arterial contraction which was lower in tumoral than in control arteries, whereas it reduced the
contraction to noradrenaline in tumoral but not in control arteries and reduced the relaxation to bradykinin in control but not
in tumoral arteries. Protein expression of VEGF-A and of the VEGF receptor FLT1 was similar in control and tumoral arteries,
but expression of the VEGF receptor KDR was increased in tumoral compared with control arteries. This suggests that tyrosine
phosphorylation may produce inhibition of the contraction in tumoral mesenteric arteries, which may increase blood flow to the
tumor when tyrosine phosphorylation is increased by stimulation of VEGF receptors.
1. Introduction
Tyrosine kinases are a family of protein kinases present in
metazoans, which are mainly associated with receptors of
growth factors such as vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), and fibroblast
growth factor (FGF) [1]. Tyrosine kinases have important
roles in several cell functions as differentiation, proliferation,
apoptosis, angiogenesis, and responses to neurotransmitters
[2]. Tyrosine kinases also play a fundamental role in the
development of malignant cells during cancer development,
and therefore several inhibitors of tyrosine kinases have been
added to the list of antitumoral agents available for cancer
treatment [3].
Tyrosine phosphorylation may also regulate contraction
of vascular smooth muscle. Vascular smooth muscle cells
show levels of tyrosine kinase activity which are relatively
high [4]. Inhibition of tyrosine phosphatase with sodium
orthovanadate produced contraction of smooth muscles of
rat aorta [5] or rat penile artery [6] and increased the
contraction to hypoxia in sheep pulmonary veins [7] and to
serotonin in rat basilar artery [8].
In tumoral tissues, tyrosine phosphorylation is often
related to activation of growth factor receptors which have
tyrosine kinase activity, including VEGF receptors which
have a central role in cancer development [9]. VEGF acts on
blood vessels mainly through two receptors: VEGF-R1/FLT1
and VEGF-R2/KDR, both of which have tyrosine kinase
2 BioMed Research International
activity [10, 11]. Expression of VEFG is increased in tumors
[12] and in the plasma of cancer patients [13, 14]. VEGF
receptors also may be increased in tumors, either in the
tumor cells or in the blood vessels supporting the tumor.
Smith et al. [15] found that VEGFR-2 is overexpressed in
blood vessels of colorectal, lung, and breast tumors, but not
in the tumor cells. However, Amaya et al. [16] have reported
increased KDR receptors in blood vessels and also in tumor
cells of colorectal cancer. These studies have localized VEGF
receptors in the microvasculature of the tumor and have not
separated the expression according to the type of blood vessel,
that is, artery, capillary, or vein. Most of the blood vessels in
the microcirculation are capillaries and venules, which have
little role in the regulation of blood flow, and there are not, to
our knowledge, studies of the expression of VEGF or VEGF
receptors specifically in the arteries supplying blood flow to
the tumor.
Regulation of tumoral vasculature is an important factor
in the development of solid tumors, as blood flow must
increase in parallel with the growth of the tumor. The
hypothesis of the present study is that tyrosine phospho-
rylation may play a role in the regulation of vasoconstric-
tion and/or vasodilatation of the arteries supplying blood
flow to the tumors. Therefore, we have studied the effect
of increasing tyrosine phosphorylation on vasoconstriction
and vasodilatation of arteries supplying colorectal tumors,
comparing them with arteries supplying normal tissue. The
inhibitors of tyrosine phosphatases such as vanadate increase
tyrosine phosphorylation and reproduce the vascular effects
of receptors with tyrosine kinase activity [17].
2. Methods
2.1. Collection of theHumanMesenteric Arteries. In this study,
arteries (0.7–1.5mm in external diameter) from 13 patients
diagnosed with colorectal tumour were used (mean age: 72 ±
4 years, 7 males and 6 females). The study was approved by
the local ethics committee and the informed consent from
all the patients was obtained before they were allowed to
participate. Arteries supplying blood flow to the tumour as
well as arteries supplying the normal colonwere dissected out
at surgery fromeachpatient and frozen ondry ice forRT-PCR
and western blot techniques, or stored in cold isotonic saline
solution for in vitro vascular response.
2.2. Recording of Vascular Response. After collection and
once transported to the laboratory, the arteries were cut into
2mm long segments and each segment was prepared for
isometric tension recording in a 4mL organ bath containing
modified Krebs-Henseleit solution at 37∘C (mM): NaCl, 115;
KCl, 4.6; KH
2
PO
4
, 1.2; MgSO
4
, 1.2; CaCl
2
, 2.5; NaHCO
3
, 25;
glucose, 11. The solution was equilibrated with 95% oxygen
and 5% carbon dioxide to a pH of 7.3-7.4. Briefly, two
fine steel wires (100 𝜇m in diameter) were passed through
the lumen of the vascular segment, one wire was fixed
to the organ bath wall while the other was connected to
a strain gauge for isometric tension recording (Universal
Transducing Cell UC3 and Statham Microscale Accessory
UL5, Statham Instruments, Inc.). This arrangement permits
passive tension to be applied in a plane perpendicular to the
long axis of the vascular cylinder. The changes in isometric
force were recorded on a Macintosh computer using Chart
v 3.6/s software and a MacLab/8e data acquisition system
(ADInstruments). An optimal passive tension of 1 g was
applied to the vascular segments, and then, they were allowed
to equilibrate for 60–90min. Before beginning the experi-
ment, the vascular segments were stimulated with potassium
chloride (50mM) to determine the contractility of smooth
muscle, and the segments which failed to contract at least
0.5 g were discarded.
To analyze the direct effect of tyrosine phosphorylation
on the vascular tone of mesenteric arteries, cumulative dose-
response curves were recorded for sodium orthovanadate
(10−4–10−2M) in the vascular segments from arteries supply-
ing the tumour (tumoral) and from those supplying normal
colon (control) in the same patients. This effect was also
recorded in the presence of the inhibitor of tyrosine kinase
genistein (10−4M) to analyze whether the response was due
to tyrosine phosphorylation. To study the effect of tyrosine
phosphorylation in response to vasoconstrictor of vasodilator
stimuli, the contraction to noradrenaline (10−9–10−4M) and
to the endothelium-dependent vasodilator bradykinin (10−9–
10−5M) was studied after treatment with orthovanadate
(10−3M) in control and tumoral arteries. Orthovanadate was
added to the organ bath 30min before the concentration-
response curve to noradrenaline or bradykinin, and before
recording the relaxation to bradykinin, the arteries were pre-
contracted with U46619 (10−9–10−8M) to reach a contractile
tone of about 3–3.5 g.
Contraction in response to sodium orthovanadate and to
noradrenaline was expressed as the percentage of the max-
imal contraction produced by potassium (50mM), whereas
the relaxation in response to bradykinin was expressed as the
percentage of the active tone achieved with U46619. In each
concentration-response curve, the pD
2
was calculated as the
negative logarithmof the concentration producing 50%of the
maximal response by geometric interpolation.
2.3. RNA Isolation and RT-PCR Analysis. Total RNA was
isolated from frozen vascular segment by using TriPure
Isolation Reagent (Roche, Group SA) protocol, as suggested
by the manufacturer. RNA concentration and integrity
were determined using RNA 6000 Nano LabChip in
an Agilent 2100 Bioanalyzer. The reverse transcription
was performed with the High Capacity RNA-to-cDNA
Master Mix (Applied Biosystems). The primers used
for amplification of cDNA were obtained from TaqMan
Gene Expression Assays (Applied Biosystems, inventoried
assays) for VEGFA (Hs03929005 m1), VEGFR1 (FLT1)
(Hs01052961 m1), VRGFR2 (KDR) (Hs00911700 m1), and
GAPDH (endogenous control 4352934E). Amplification
of target cDNA was done using a 7900HT Fast Real-Time
PCR System with the following standardized thermal
cycling conditions: 50∘C for 2min, 95∘C for 10min, followed
by 40 cycles of 95∘C for 15 sec and 60∘C for 1min. All
RT-PCR reactions were run in duplicate. Threshold cycle
BioMed Research International 3
(Ct) was determined for both target gene and GAPDH for
each sample, and relative quantifying of both genes was
determined with the 2-DDCt method [18].
2.4. Western Blot Analysis. The expression of VEGF-A, KDR,
and FLT1 in vascular samples was measured by densitometry
quantitation of immunoblots. Briefly, vascular tissues were
homogenized in a lysis buffer (in mM): 50 Tris-HCl, 125
NaCl, 1 EDTA, 1 EGTA, 1% Nonidet (NP-40) containing
5% complete mini-tab cocktail protease inhibitor (Roche
Biochemicals) and centrifuged at 10000 rpm for 15min at
4∘C. Protein concentration was determined using a modified
Lowry method [19]. Then, 50𝜇g of total protein was resolved
in 12% SDS-PAGE and electrophoretically transferred onto
a PVDF-membrane using Mini Trans-Blot cell (BioRad
laboratories, CA, USA). Membranes were blocked in 5%
skim milk for 1 h at room temperature. After an overnight
incubation at 4∘C using diluted monoclonal antibodies
from Sigma (1 : 1000), the membranes were incubated with
1 : 2500 diluted horseradish peroxidase-conjugated secondary
antibody (Sigma-Aldrich). The blots were then visualized
using ImmunoStar HRP Substrate Kit (Bio-Rad) according
tomanufacturer’s instructions. Relative densities of the bands
were analyzed using ImageGauge v 4.0, Fujifilm.Theproteins
were normalized with tubulin.
Antibodies are monoclonal anti-VEGF-A, monoclonal
anti-VEGF receptor 1 (FLT1), monoclonal anti-VEGF recep-
tor 2 (KDR), diluted at (1 : 1000), polyclonal anti-tubuline
(1 : 1000) (Sigma Aldrich).
2.5. Statistical Analysis. The data are expressed as
mean± standard error of the mean. The responses to
orthovanadate, noradrenaline, and bradykinin in tumour
and control vascular segments, treated and untreated with
genistein or orthovanadate, were compared by two-way
ANOVA followed by Bonferroni test to determine which
comparisons were statistically significant. Genic and protein
expression of VEGF, FLT1, and KDR in control and tumoral
arteries were compared by paired Student’s 𝑡-test.
2.6. Compounds Used. The compounds used were (all from
Sigma) sodium orthovanadate (Na
3
VO
4
); genistein (5,7-
dihydroxy-3-(4-hydroxyphenyl)-4H-benzopyran-4-one,
4,5,7-trihydroxy-isoflavone); L-noradrenaline ((1R)-4-(2-
amino-1-hydroxyethyl)-1,2-benzenediol); bradykinin acetate
(Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), U46619 (9,11-
dideoxy-11𝛼,9𝛼-epoxymethano prostaglandin F2𝛼).
3. Results and Discussion
Stimulation with potassium chloride (50mM) produced a
similar contraction in tumoral (3.27 ± 0.22 g) and control
(3.18 ± 0.28 g) arteries. Sodium orthovanadate produced
concentration-dependent contraction, which was smaller in
tumoral (𝑛 = 10) compared to control (𝑛 = 9) arteries
(Figure 1). This contraction to orthovanadate was reduced by
genistein, both in tumoral and control arteries (𝑛 = 4 in both
groups).
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Figure 1: Contraction in response to sodium orthovanadate (10−4–
10−2M) of mesenteric arteries supplying colorectal tumours (tumor,
𝑛 = 10) and those supplying normal colon (control, 𝑛 = 9), in the
absence or in the presence of genistein (10−4M, 𝑛 = 4). Values are
represented asmean± SEM. ∗𝑃 < 0.05 statistically significant versus
control.
Noradrenaline also produced concentration-dependent
contraction, which was similar in control and tumoral arter-
ies (pD
2
= 6.20 ± 0.07, 𝑛 = 6 versus 6.52 ± 0.23, 𝑛 =
6, resp.) (Figure 2). In control arteries, pretreatment with
sodium orthovanadate did not modify the contraction to
noradrenaline (pD
2
= 6.13 ± 0.35, 𝑛 = 7), whereas in tumoral
arteries, the contraction to noradrenaline in the segments
treated with orthovanadate was smaller (pD
2
= 5.68 ± 0.12,
𝑛 = 6, 𝑃 < 0.05) than that in untreated segments.
In the segments precontracted with U46619, bradykinin
produced concentration-dependent relaxation, which was
similar in the control and tumoral arteries (pD
2
= 6.89 ±
0.30, 𝑛 = 7 versus 7.11 ± 0.24, 𝑛 = 7, resp.) (Figure 3). Treat-
ment with sodium orthovanadate reduced this relaxation in
control arteries (pD
2
= 6.00 ± 0.15, 𝑛 = 8, 𝑃 < 0.05);
however, in tumoral arteries, this treatment did not modify
the relaxation to bradykinin (pD
2
= 6.67 ± 0.27, 𝑛 = 8). The
contractile tone produced by U46619 was similar in control
and tumoral arteries, with and without pretreatment with
sodium orthovanadate.
Quantitative PCR-RT analysis revealed a significant
decrease in VEGF-A expression in tumor samples compared
to the control (1.18 ± 0.20 versus 0.36 ± 0.06, 𝑃 < 0.05). We
have also determined the expression of KDR and FLT1, the
main receptors of VEGF-A in the arteries [20]. Compared
with the control, the vascular mRNA gene expression of KDR
and FLT1 from tumor samples was significantly downreg-
ulated (60% and 64%, resp., 𝑃 < 0.05). As a control, the
expression of GAPDH was measured in parallel using the
same mRNA samples (Figure 4).
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Figure 2: Contraction in response to noradrenaline (10−9–10−4M)
of mesenteric arteries supplying colorectal tumours (tumour, 𝑛 = 6)
and those supplying normal colon (control, 𝑛 = 6), untreated or
treated (𝑛 = 6-7) with sodium orthovanadate (10−3M). Values are
represented as mean ± SEM. ∗∗𝑃 < 0.01; ∗𝑃 < 0.05 statistically
significant versus untreated segments.
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Figure 3: Relaxation in response to bradykinin (10−9–10−5M) of
mesenteric arteries supplying colorectal tumours (tumour, 𝑛 = 7)
and those supplying normal colon (control, 𝑛 = 7), precontracted
with U46619 and untreated or treated (𝑛 = 8) with sodium
orthovanadate (10−3M). Values are represented as mean ± SEM.
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Figure 4: RT-PCR analysis of mRNA expression for VEGF-A,
FLT1, and KDR in mesenteric arteries supplying colorectal tumours
(tumour, 𝑛 = 6) and those supplying normal colon (control, 𝑛 = 6).
Values were normalized to GAPDH mRNA expression. Data are
presented as mean ± SEM. ∗𝑃 < 0.05 statistically significant versus
control samples.
Nextwe investigated theVEGF-A, FLT1, andKDRprotein
expression by western blot analysis. We found that protein
expression of VEGF-A and FLT1 was similar in control and
tumor vascular tissues. However, in samples from tumors,
there is a significant increase in the protein expression ofKDR
(Figure 5).
This study finds that tyrosine phosphorylation may
underlie a differential regulation of vascular function in
colorectal tumors. Tyrosine phosphorylation is known to
produce vasoconstriction of vascular [5] and nonvascular
[21–24] smooth muscles. In our study, inhibition of tyrosine
phosphatases by orthovanadate indeed produced vasocon-
striction of mesenteric arteries. This contraction was inhib-
ited by the tyrosine kinase inhibitor genistein, suggesting
that it is due to increased tyrosine phosphorylation. The
contraction produced by tyrosine phosphorylation has been
related to Ca2+ influx [6, 25] or increased sensitivity to Ca2+
of the intracellular contractile mechanisms [26, 27].
Although orthovanadate contracted both control and
tumoral arteries, the contraction was smaller in tumoral
arteries, suggesting a reduced contractile effect of tyrosine
phosphorylation in these arteries. Also, we have found that
orthovanadate reduced the contraction to noradrenaline in
tumoral arteries but not in control arteries. This contrasts
with observations in rabbit aorta and mesenteric arteries, in
which tyrosine phosphorylation increases adrenergic vaso-
constriction [28]; therefore, the inhibitory effect observed
in the present study may be specific for tumoral arteries. If
tyrosine phosphorylation has an inhibitory effect in tumoral
but not in normal arteries, it might also explain the small
contraction produced by orthovanadate in tumoral arteries,
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Figure 5: Protein expression in mesenteric arteries supplying colorectal tumours (T, 𝑛 = 10) and those supplying normal colon (C, 𝑛 = 10).
VEGF-A, FLT1, KDR, and 𝛼-tubuline expression was determined by western blot. Data are presented as means ± SEM. ∗𝑃 < 0.05 statistically
significant versus control samples.
as the inhibitory effect might counteract the vasoconstriction
observed in control arteries.
Orthovanadate also reduced endothelium-dependent
vasodilatation in control mesenteric arteries. The effects of
tyrosine phosphorylation on the endotheliummay be mixed.
Tyrosine kinases may enhance the release of endothelial
nitric oxide [8, 29–33]. However, tyrosine phosphorylation
has been also related to the endothelial dysfunction in
diabetes [33], hyperhomocysteinemia [34], and Raynaud’s
phenomenon [35]. Our results agree with those latter studies,
as in control mesenteric arteries, orthovanadate reduced
endothelium-dependent vasodilatation to bradykinin. How-
ever, in tumoral arteries orthovanadate did not reduce signif-
icantly this relaxation.Thismay agree with a possible relaxing
effect of tyrosine phosphorylation in these arteries, as we
have hypothesized above, which could compensate for the
relaxation impairment observed in control arteries.
This possible inhibitory effect of tyrosine phosphoryla-
tion in tumoral arteries may be surprising, as the activation
of tyrosine phosphorylation produces vasoconstriction in
normal arteries [8, 36–39]. However, some receptors with
tyrosine kinase activity may produce vasodilatation. Vascular
endothelial growth factor (VEGF) produces vasodilatation
in human [40], pig [41], or rat [42] coronary circulation,
human placental circulation [43], bovine pulmonary arteries
[44], and human mammary and radial arteries [45, 46].
Indeed, we have observed that application of VEGF pro-
duced relaxation of precontracted human mesenteric blood
vessels (unpublished observations). Vanadate compounds are
known to increase phosphorylation of VEGFR2/KDR recep-
tors [47–49] and activate their effects [47, 49]. Therefore, as
VEGFR2/KDR receptors may produce vasodilatation [50–
52] and may be activated by vanadate, this may explain the
inhibitory effect of orthovanadate observed in tumoral arter-
ies. Also, we have found in this study that the expression of
KDR receptors is increased in tumoral arteries and this might
explain why this inhibitory effect is apparent in tumoral but
not in control arteries. Expression of VEGFR-1/Flt1 [53, 54],
VEGFR2/KDR [15, 55, 56], or both receptor subtypes [57–60]
is increased in several types of tumors including colorectal
ones [61–63]. However, the present study is the first, to our
knowledge, showing increased expression of VEGF receptors
in the arteries supplying blood flow to the tumor.These arter-
ies are notmutated, while tumoral cells are, butmay be altered
by factors released in the microenvironment of the tumor
[64]. It has been described that the arteries surrounding
the tumor show differences in receptor expression compared
with normal arteries from the same subject [65]. As it has
been described that VEGF receptors are expressed mainly in
the endothelium [66], this increased expression in tumoral
arteries might explain why tyrosine phosphorylation has a
partly inhibitory effect in these arteries but not in normal
arteries. In normal arteries, tyrosine phosphorylation would
produce contraction of smooth muscle, as we have observed,
but in tumoral arteries, due to the increased expression of
VEGF receptors, it would activate also relaxing mechanisms
in endothelial cells. Contrasting with the fact that in tumoral
arteries protein expression of FLT1 and KDR was unchanged
or increased, respectively, the genic expression of these recep-
tors was reduced in tumoral arteries. It has been shown that
the VEGF may have opposite effects on protein and mRNA
expression of FLT1 and KDR receptors in cultured human
umbilical vein endothelial cells, which may be an adaptive
mechanism to compensate for receptor desensitization and
allow recovery of responsiveness to VEGF [64].
4. Conclusions
These results may have relevance, as the medium in the
vicinity of the tumour may be rich in factors that activate
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tyrosine kinases and inhibitors of tyrosine kinase are used as
antitumoral agents. Our results suggest that in normal arter-
ies, tyrosine phosphorylation may produce vasoconstriction,
whereas in the arteries supplying the tumor, it may produce
inhibition of contraction.This may redistribute blood flow to
the tumor, thus facilitating its growth.
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